Seeking Cold Chain Efficiency - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Seeking Cold Chain Efficiency
Medication safety and efficacy depend on maintaining products at the proper temperature.

Pharmaceutical Technology
Volume 37, Issue 2

Maria Toutoudaki/Selahattin BAYRAM/Getty Images; Dan Ward
Pharmaceutical manufacturers devote considerable time and resources to implement effective cold-chain practices that protect products, especially sensitive biopharmaceuticals, blood products, and vaccines, from damage. Although efforts have traditionally focused on refrigerated (2–8 C) and frozen (-20 C) products, there is growing attention to controlled room temperature (CRT) products, which require maintenance at 15–25 C to ensure quality and efficacy.

The emphasis on CRT shipments, expanding volumes of biologics, and rising demand from emerging markets are spurring strong growth for goods and services related to temperature-controlled logistics, particularly in Asia and the southern hemisphere. According to the 2012 Biopharma Cold Chain Sourcebook, published by Pharmaceutical Commerce, cold-chain logistics spending is forecast to grow approximately 12% from $6.5 billion in 2010 to $7.6 billion in 2013 and increase another 12.6% to reach $8.9 billion in 2016. Packaging, including instrumentation, accounts for about 37% of the dollars spent on cold-chain logistics. The focus on CRT shipments is particularly strong in Canada, Israel, Ireland, the European Union, Turkey, Saudi Arabia, and South Korea, according to Prakash Mahesh, vice-president of marketing and business development at Sonoco Protective Solutions, ThermoSafe Brands, formerly part of Tegrant.

Evolving global regulations

Regulations involving the cold chain are undergoing change. "South America, Mexico, South Africa, Saudi Arabia, and others are enforcing strict label claims," says Mahesh. In fact, he says, the European Medicines Agency (EMA) is pushing toward strict label claims and "will likely require 'proof' of protection come 2013."

With evolving regulations worldwide and dramatic growth in the number of temperature-sensitive products, it's more essential than ever to manage conditions in storage and transit. "Late-phase clinical development teams understand the need to maintain strict temperature adherence to ensure the positive outcomes in their trials as well as maintaining patient safety," says Andrew J. Mills, CEO of Americas for Intelsius, a DGP company and supplier of temperature-controlled packaging. He explains that some of the drugs coming on the market "can become toxic if frozen...or lose efficacy very quickly if warmed."

In addition, he says, "The increased FDA/EMA collaboration in overseas inspections is making the need for good cold-chain practices felt all over the globe." He explains, this regulatory attention is not only encouraging adoption of good cold-chain practices from new sectors of the marketplace, but also "bringing emerging markets up to speed with good distribution practices (GDP) compliance faster."

An e-pedigree law, scheduled to go into effect on Jan. 1, 2015 in California, is encouraging drug makers to adopt technologies that will implement traceability and cold-chain management simultaneously. A number of organizations offer resources to help companies follow GDP, including the United Kingdom's Medicines and Healthcare Products Regulatory Agency (MHRA) (1). For links to these resources, see the online version of this article at


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

What impact do mega-mergers of biopharmaceutical companies have on the development of new drugs?
Improves the quality and number of innovative drugs available to patients.
Restricts innovation and the development of new drugs.
Has no impact on drug development.
Do not know.
Improves the quality and number of innovative drugs available to patients.
Restricts innovation and the development of new drugs.
Has no impact on drug development.
Do not know.
Eric Langer Outsourcing Outlook Eric LangerOutsourcing No Longer Just for Cost-Cutting
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerSeeking Alternative Catalyst Solutions
Jill Wechsler Regulatory Watch Jill Wechsler Global Expansion Shapes Drug Oversight
Chris Burgess Statistical Solutions Chris BurgessIs a Sample Size of n=6 a Magic Number?
Sean Milmo European Regulatory WatchSean MilmoRegulating the Environmental Impact of Pharmaceuticals
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
USP Faces New Challenges
Report: Pfizer Makes $101 Billion Offer to AstraZeneca
Source: Pharmaceutical Technology,
Click here